S&P 500

CRL

Charles River Laboratories International, Inc.

latest move

+7.09%

2026-10-05

7 sessions · 2026-06-29 → 2026-10-05 · avg 15.83% · largest 24.24%

Charles River Laboratories International, Inc. is a global drug discovery and preclinical development services provider that supplies laboratory animal models and outsourced research services.

Price history

stitched from the price window carried by each report

Every session it moved

newest first

2026-10-05Bullish

+7.09%24 hours change

Strong sector rotation and analyst price target upgrades following raised FY2026 guidance drove the stock to a new 52-week high.

read the report →

2026-09-24Bullish

+6.17%24 hours change

The stock rose after management reaffirmed FY2026 financial guidance at the upper end and unveiled its 2030 targets at Investor Day.

read the report →

2026-08-11Bullish

+20.45%weekly change

Shares surged after Charles River reported strong Q2 2026 earnings, returned to organic revenue growth, and raised full-year guidance.

read the report →

2026-08-10Bullish

+19.98%weekly change

CRL surged following strong Q2 2026 earnings, a return to positive organic revenue growth, raised full-year guidance, and analyst upgrades.

read the report →

2026-08-05Bullish

+11.36%24 hours change

CRL stock surged following a strong Q2 2026 earnings beat and an across-the-board upward revision to full-year 2026 financial guidance.

read the report →

2026-06-30Bullish

+21.54%weekly change

The stock surged following a Morgan Stanley upgrade and the announcement of a strategic AI drug discovery partnership with Eli Lilly.

read the report →

2026-06-29Bullish

+24.24%weekly change

Morgan Stanley upgraded CRL to Overweight on signs that recovering biopharma funding is translating into increased R&D bookings.

read the report →